Please use this identifier to cite or link to this item: http://hdl.handle.net/10668/1324
Título : Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
Autor : Ritte, Rebecca
Lukanova, Annekatrin
Berrino, Franco
Dossus, Laure
Tjønneland, Anne
Olsen, Anja
Overvad, Thure Filskov
Overvad, Kim
Clavel-Chapelon, Françoise
Fournier, Agnès
Fagherazzi, Guy
Rohrmann, Sabine
Teucher, Birgit
Boeing, Heiner
Aleksandrova, Krasimira
Trichopoulou, Antonia
Lagiou, Pagona
Trichopoulos, Dimitrios
Palli, Domenico
Sieri, Sabina
Panico, Salvatore
Tumino, Rosario
Vineis, Paolo
Quirós, José Ramón
Buckland, Genevieve
Sánchez, Maria-José
Amiano, Pilar
Chirlaque, María-Dolores
Ardanaz, Eva
Sund, Malin
Lenner, Per
Bueno-de-Mesquita, Bas
van Gils, Carla H
Peeters, Petra Hm
Krum-Hansen, Sanda
Gram, Inger Torhild
Lund, Eiliv
Khaw, Kay-Tee
Wareham, Nick
Allen, Naomi E
Key, Timothy J
Romieu, Isabelle
Rinaldi, Sabina
Siddiq, Afshan
Cox, David
Riboli, Elio
Kaaks, Rudolf
Filiación: [Ritte,R; Lukanova,A; Dossus,L; Rohrmann,S; Teucher,B; Kaaks,R] Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany. [Berrino,F] Department of Ritte et al. Breast Cancer Research Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy. [Tjønneland,A; Olsen,A] Institute of Cancer Epidemiology, Danish Cancer Society, Copenhagen, Denmark. [Overvad,TF] Department of Cardiology, Aalborg Hospital, Aarhus University Hospital, Aalborg, Denmark. [Overvad,K] Department of Epidemiology, School of Public Health, Aarhus University, Aarhus, Denmark. [Clavel-Chapelon,F; Fournier,A; Fagherazzi,G] Centre for Research in Epidemiology and Population Health, INSERM, Institut Gustave Roussy, Villejuif, France. Paris South University, Villejuif, France. [Rohrmann,S] Division of Cancer Epidemiology and Prevention, Institute of Social and Preventive Medicine, Zurich, Switzerland. [Boeing,H; Aleksandrova,K] Department of Epidemiology, German Institute of Human Nutrition, Potsdam-Rehbruecke, Nuthetal, Germany. [Trichopoulou,A; Lagiou,P] WHO Collaborating Center for Food and Nutrition Policies, Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, Goudi, Athens, Greece. [Trichopoulou, A] Hellenic Health Foundation, Athens, Greece. [Trichopoulos,D] Department of Epidemiology, Harvard School of Public Health, Boston, USA. Bureau of Epidemiologic Research, Academy of Athens, Athens, Greece. [Palli,D] Molecular and Nutritional Epidemiology Unit, Cancer Research and Prevention Institute (ISPO), Scientific Institute of Tuscany, Florence, Italy. [Sieri,S] Nutritional Epidemiology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy. [Panico,S] Department of Clinical and Experimental Medicine Medical School Federico II University, Naples, Italy. [Tumino, R] Cancer Registry and Histopathology Unit, ‘Civile M.P. Arezzo’ Hospital ASP 7, Ragusa, Italy. [Vineis,P; Riboli,E] Centre for Environment and Health School of Public Health, Imperial College London, London, UK. [Vineis,P] Human Genetics Foundation (HuGeF), Torino, Italy. [Quirós,JR] Public Health and Health Planning Directorate, Asturias, Spain. [Buckland,G] Unit of Nutrition, Environment and Cancer, Cancer Epidemiology Research Programme, Catalan Institute of Oncology (ICO-IDIBELL), Barcelona, Spain. [Sánchez,MJ] Andalusian School of Public Health, Granada, Spain. [Sánchez,MJ; Amiano,P; Chirlaque,MD; Ardanaz,E] CIBER de Epidemiología y Salud Pública (CIBERESP), Madrid, Spain. [Amiano,P] Public Health Division of Gipuzkoa, Institute BIO Donostia, Health Department, Basque Region, Gipuzkoa, Spain. [Chirlaque,MD] Department of Epidemiology, Murcia Regional Health Authority, Murcia, Spain. [Ardanaz,E] Navarra Public Health Institute, Pamplona, Spain. [Sund,M] Department of Surgery and Perioperative Sciences, Umeå University Hospital, Umeå, Sweden. [Lenner,P] Department of Oncology and Radiation Sciences, Oncology, Umeå University Hospital, Umeå, Sweden. [Bueno-de-Mesquita,B] National Institute for Public Health and the Environment, Bilthoven, The Netherlands. Department of Gastroenterology and Hepatology, University Medical Centre, Utrecht, The Netherlands. [van Gils,CH; Peeters,PHM] Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands. [Peeters,PHM; Siddiq,A; Cox,D] Department of Epidemiology and Biostatistics, School of Public Health, Faculty of Medicine, Imperial College, London, London, UK. [Krum-Hansen,S; Gram,IT; Lund,E] Institute of Community Medicine, University of Tromsø, Tromsø, Norway. [Khaw,KT] School of Clinical Medicine, University of Cambridge, The Old Schools, Trinity Lane, Cambridge, UK. [Wareham,N] Medical Research Council, Epidemiology Unit, Addenbrooke’s Hospital, Cambridge, UK. [Allen,NE; Key,TJ] Cancer Epidemiology Unit, University of Oxford, Oxford, UK. [Romieu,I; Rinaldi,S] Nutritional Epidemiology Group, Section of Nutrition and Metabolism, International Agency for Research on Cancer (IARC), Lyon, France. [Siddiq,A] Department of Genomics of Common Disease, School of Public Health, Imperial College London, London UK.
Palabras clave : Receptores de Progesterona
Receptores Estrogénicos
Factores de Edad
Adiposidad
Neoplasias de la mama
Estudios de cohortes
Estudios Prospectivos
Factores de riesgo
MeSH: Medical Subject Headings::Named Groups::Persons::Age Groups::Adult
Medical Subject Headings::Health Care::Health Care Quality, Access, and Evaluation::Quality of Health Care::Epidemiologic Factors::Age Factors
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Aged
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Aged::Aged, 80 and over
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Mass Index
Medical Subject Headings::Diseases::Neoplasms::Neoplasms by Site::Breast Neoplasms
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Therapeutics::Drug Therapy::Hormone Replacement Therapy::Estrogen Replacement Therapy
Medical Subject Headings::Check Tags::Female
Medical Subject Headings::Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Aged
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Middle Aged
Medical Subject Headings::Phenomena and Processes::Reproductive and Urinary Physiological Phenomena::Reproductive Physiological Phenomena::Climacteric::Menopause::Premenopause
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Prospective Studies
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Estrogen
Medical Subject Headings::Chemicals and Drugs::Amino Acids, Peptides, and Proteins::Proteins::DNA-Binding Proteins::Receptors, Cytoplasmic and Nuclear::Receptors, Steroid::Receptors, Progesterone
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors
Medical Subject Headings::Named Groups::Persons::Age Groups::Adult::Young Adult
Medical Subject Headings::Analytical, Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Body Constitution::Body Weights and Measures::Body Fat Distribution::Adiposity
Fecha de publicación : 14-May-2012
Editorial : BioMed Central
Cita Bibliográfica: Ritte R, Lukanova A, Berrino F, Dossus L, Tjønneland A, Olsen A, et al. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study. Breast Cancer Res. 2012; 14(3):R76
Abstract: INTRODUCTION Associations of hormone-receptor positive breast cancer with excess adiposity are reasonably well characterized; however, uncertainty remains regarding the association of body mass index (BMI) with hormone-receptor negative malignancies, and possible interactions by hormone replacement therapy (HRT) use. METHODS Within the European EPIC cohort, Cox proportional hazards models were used to describe the relationship of BMI, waist and hip circumferences with risk of estrogen-receptor (ER) negative and progesterone-receptor (PR) negative (n = 1,021) and ER+PR+ (n = 3,586) breast tumors within five-year age bands. Among postmenopausal women, the joint effects of BMI and HRT use were analyzed. RESULTS For risk of ER-PR- tumors, there was no association of BMI across the age bands. However, when analyses were restricted to postmenopausal HRT never users, a positive risk association with BMI (third versus first tertile HR = 1.47 (1.01 to 2.15)) was observed. BMI was inversely associated with ER+PR+ tumors among women aged ≤49 years (per 5 kg/m2 increase, HR = 0.79 (95%CI 0.68 to 0.91)), and positively associated with risk among women ≥65 years (HR = 1.25 (1.16 to 1.34)). Adjusting for BMI, waist and hip circumferences showed no further associations with risks of breast cancer subtypes. Current use of HRT was significantly associated with an increased risk of receptor-negative (HRT current use compared to HRT never use HR: 1.30 (1.05 to 1.62)) and positive tumors (HR: 1.74 (1.56 to 1.95)), although this risk increase was weaker for ER-PR- disease (Phet = 0.035). The association of HRT was significantly stronger in the leaner women (BMI ≤22.5 kg/m2) than for more overweight women (BMI ≥25.9 kg/m2) for, both, ER-PR- (HR: 1.74 (1.15 to 2.63)) and ER+PR+ (HR: 2.33 (1.84 to 2.92)) breast cancer and was not restricted to any particular HRT regime. CONCLUSIONS An elevated BMI may be positively associated with risk of ER-PR- tumors among postmenopausal women who never used HRT. Furthermore, postmenopausal HRT users were at an increased risk of ER-PR- as well as ER+PR+ tumors, especially among leaner women. For hormone-receptor positive tumors, but not for hormone-receptor negative tumors, our study confirms an inverse association of risk with BMI among young women of premenopausal age. Our data provide evidence for a possible role of sex hormones in the etiology of hormone-receptor negative tumors.
Descripción : Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't;
URI: http://hdl.handle.net/10668/1324
Versión del editor : http://breast-cancer-research.com/content/14/3/R76/abstract
DOI: 10.1186/bcr3186
ISSN : 1465-542X (Online)
1465-5411 (Print)
Appears in Collections:01- Artículos - EASP. Escuela Andaluza de Salud Pública

Files in This Item:
File Description SizeFormat 
Ritte_AdiposityHormone.pdf399,11 kBAdobe PDFView/Open
bcr3186-s1.xls23 kBMicrosoft ExcelView/Open
bcr3186-s2.ppt160,5 kBMicrosoft PowerpointView/Open
bcr3186-s3.ppt156 kBMicrosoft PowerpointView/Open
bcr3186-s4.ppt155 kBMicrosoft PowerpointView/Open
bcr3186-s5.ppt156 kBMicrosoft PowerpointView/Open
bcr3186-s6.xls27,5 kBMicrosoft ExcelView/Open
bcr3186-s7.xls29,5 kBMicrosoft ExcelView/Open
bcr3186-s8.xls34 kBMicrosoft ExcelView/Open
bcr3186-s9.xls28 kBMicrosoft ExcelView/Open
bcr3186-s10.ppt150,5 kBMicrosoft PowerpointView/Open
bcr3186-s11.ppt143,5 kBMicrosoft PowerpointView/Open


Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.